Abstract

Morbidity and mortality of cancer increases year by year in Japan, in this rapid aging society. Independent of cancer, heart failure is now a common cardiovascular disease, which can occur mainly due to life-style diseases in the elderly people; however, it is obviously related to cancer therapy in some population of heart failure. Further, due to the newly progressed cancer therapies, many patients with cancer are able to survive longer than before. These “cancer survivors” will develop heart failure probably due to side effects of anti-cancer drugs or their original life-style diseases. However, less is known in this issue, especially in Japan. Therefore, we have started Kurume University Cardio-Renal Oncology registry (Kurume-CREO registry), which is a prospective, observational and single-center study to monitor the development of cardiovascular and renal diseases, including side effects of anti-cancer drugs, in patients with hematologic malignancies and breast cancer in Kurume University Hospital. Currently, we have enrolled 133 patients, who have been monitored by electrocardiogram, chest X-ray, blood and urine tests for the early diagnosis and early treatment to cancer-related cardiovascular and renal diseases. This study can be also a systematic research in the monitoring system and the risk prediction, including the surveillance of Japanese elderly patients with cancer. In this session, we will discuss our monitoring system current progress in this study.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.